TerminatedPhase 2NCT05122182

Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Sydney
Principal Investigator
Meg Jardine
NHMRC Clinical Trials Centre, The University of Sydney
Intervention
Candesartan Cilexetil(drug)
Enrollment
49 target
Eligibility
18 years · All sexes
Timeline
20222023

Study locations (10)

Collaborators

The George Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05122182 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials